Aligos Therapeutics (ALGS) EBITDA (2019 - 2026)

Aligos Therapeutics has reported EBITDA for 8 years, with the latest figure at -$23.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 153.55% year-over-year to -$23.1 million; the trailing twelve-month figure through Mar 2026 stood at -$90.3 million (down 69.51% YoY), and the FY2025 full-year result was -$24.2 million, up 81.59% from the prior year.
• EBITDA for Q1 2026 stood at -$23.1 million, down from -$19.9 million in the prior quarter.
• The five-year high for EBITDA was $43.1 million in Q1 2025, with the low at -$82.3 million in Q4 2024.
• Historically, EBITDA has averaged -$21.3 million across 5 years, with a median of -$20.1 million in 2022.
• The largest YoY upside for EBITDA was 223.34% in 2025 against a maximum downside of 412.86% in 2025.
• Aligos Therapeutics' EBITDA stood at -$21.6 million in 2022, then slipped by 28.65% to -$27.8 million in 2023, then sank by 195.49% to -$82.3 million in 2024, then soared by 75.85% to -$19.9 million in 2025, then declined by 16.12% to -$23.1 million in 2026.
• The last three EBITDA figures came in at -$23.1 million (Q1 2026), -$19.9 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.